Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

5.95
+0.30005.31%
Post-market: 5.75-0.1999-3.36%19:53 EDT
Volume:340.86K
Turnover:1.98M
Market Cap:40.83M
PE:-0.82
High:5.98
Open:5.52
Low:5.48
Close:5.65
52wk High:30.50
52wk Low:2.90
Shares:6.86M
Float Shares:6.34M
Volume Ratio:0.44
T/O Rate:5.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.2500
EPS(LYR):-48.8611
ROE:-522.50%
ROA:-83.29%
PB:10.22
PE(LYR):-0.12

Loading ...

Company Profile

Company Name:
Plus Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
28
Office Location:
6420 LEVIT GREEN BOULEVARD,SUITE 210,Houston,Texas,United States
Zip Code:
77021
Fax:
210 974 6901
Introduction:
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Directors

Name
Position
Marc H. Hedrick
President, Chief Executive Officer and Director
Richard J. Hawkins
Chairman of the Board
An van Es Johansson
Director
Howard Clowes
Director
Kyle Guse Esq
Director
Robert Lenk
Director

Shareholders

Name
Position
Marc H. Hedrick
President, Chief Executive Officer and Director
Andrew Sims
Chief Financial Officer